Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN3009 |
Synonyms | |
Therapy Description |
GEN3009 is a bivalent CD37 monoclonal antibody with enhanced hexamerization ability, which potentially induces antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity, and results in reduced tumor growth (PMID: 32341336). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN3009 | GEN-3009|GEN 3009|DuoHexaBody-CD37 | CD37 Antibody 8 | GEN3009 is a bivalent CD37 monoclonal antibody with enhanced hexamerization ability, which potentially induces antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity, and results in reduced tumor growth (PMID: 32341336). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04358458 | Phase Ib/II | GEN3009 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Terminated | USA | NLD | ESP | DNK | BEL | 0 |